Zealand Pharma

Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. Its products include Zegalogue and V-Go. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on April 1, 1997 and is headquartered in Soborg, Denmark.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023 Strong progress across obesity pipeline, first PDUFA date for dasiglucagon in CHI in 2023 and solid financial position Boehringer Ingelheim advances GCGR/GLP-1R dual agonist survodutide (BI456906) into Phase 3 trials in obesity Zealand presents amylin analog ZP8396 6-week trial results at ObesityWeek and initiates GLP-1R/GLP-2R dual agonist dapiglutide 13-week dose titration trial Zealand to host Obesity R&D Event in London on December 5th Dasiglucagon for congenital hyperinsulinism granted Priority Review with December 30, 2023 PDUFA date for up to three weeks of dosing; plans to make product available in the US as soon as possible following potential approval Revenue recognized for expected milestone payments from existing partnerships of EUR 30 million and USD 10 million respectively, contributing to the solid financial position Copenhagen, Denmark, November 9, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma Announces Financial Results for the First Nine Months of 2023

Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023

Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand Pharma A/S (CVR-no.

Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results

Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no.

Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease

Press release – No. 11 / 2023 SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023 Copenhagen, Denmark, September 8, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023

Press release – No. 10 / 2023 Zealand Pharma to participate in upcoming healthcare conferences in September 2023 Copenhagen, Denmark, September 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma to participate in upcoming healthcare conferences in September 2023

Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review designation to dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism (CHI) for up to 3 weeks of dosing with a Prescription Drug User Fee Act (PDUFA) date on December 30, 2023.

Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism

Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance sheet Boehringer Ingelheim to move into Phase 3 trials with GCGR/GLP-1R dual agonist survodutide (BI456906) in obesity following positive Phase 2 data Encouraging weight loss and tolerability data from long-acting amylin analog ZP8396 Regulatory submission of NDA to the US FDA for dasiglucagon in congenital hyperinsulinism and submission of MAA to EMA for dasiglucagon for the treatment of severe hypoglycemia Strengthened balance sheet with DKK 1.5 billion, resulting in a runway to mid-2026 Copenhagen, Denmark, August 17, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma Announces Financial Results for the First Half of 2023

Press Release – No. 9 / 2023 Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results Copenhagen, Denmark, August 14, 2023 – a Zealand Pharma A/S (CVR-no.

Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results

Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396 administered once-weekly for six weeks led to 5.3% and 5.1% mean weight loss as compared to 2.6%, 3.6% and 4.2% weight loss following single doses of 0.7, 1.4 and 2.4 mg ZP8396, already reported Part 2 investigates once-weekly dosing for 16 weeks and has been initiated, exploring significantly higher doses of ZP8396 based on the mild adverse event profile observed in Part 1 of the trial Results support continued development of ZP8396 as an alternative to GLP-1-based therapies for the management of overweight and obesity Copenhagen, Denmark, July 3, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396

Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism

Press release – No. 7 / 2023 Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency Copenhagen, Denmark June 26, 2023  – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean of 4.2% from baseline (4.8% placebo-corrected) within one week following a single dose of ZP8396 and were well-sustained over six weeks of observation In development as an alternative non-incretin peptide therapy for the potential management of overweight and obesity A 16-week multiple ascending dose (MAD) study of ZP8396 has been initiated Copenhagen, Denmark, June 24, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no.

Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions

INGELHEIM, Germany & COPENHAGEN, Denmark--(BUSINESS WIRE)--Nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906).

Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1

Press Release­­­­­­­ No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1 Up to 40% of people who reached the highest two doses of survodutide (BI 456906) achieved a weight loss of at least 20%1 Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite2 Detailed data were presented at the 2023 American Diabetes Association's 83rd Scientific Sessions Ingelheim, Germany, and Copenhagen, Denmark, 23 June, 2023 – Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association's 83rd Scientific Sessions in San Diego, CA, U.S. The Phase II study included two analyses: planned (assigned dose at randomization, which was also the primary endpoint) and actual (dose at the end of treatment).1 People who completed the study on the 4.8 mg dose (actual treatment analysis) achieved nearly 19% weight loss.1 As previously announced, the planned treatment analysis demonstrated nearly 15% weight loss for all those randomized to the 4.8 mg dose.1 Bodyweight reductions with survodutide had not reached a plateau at week 46, suggesting additional weight loss could be achieved with longer treatment duration.1 “Given the prevalence of obesity and its many disease-related complications, there is a dire need for treatments that can help treat the disease of obesity effectively,” said Carel le Roux, MD, Ph.D.

Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)

Press release – No. 4 / 2023 Zealand Pharma to Participate in Upcoming Healthcare Conferences Copenhagen, Denmark, June 6, 2023 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.

Zealand Pharma to Participate in Upcoming Healthcare Conferences

Zealand Pharma A/S. (ZEAL) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO Henriette Wennicke - CFO David Kendall - CMO Conference Call Participants Charlie Muir - Morgan Stanley Michael Novod - Nordea Jesper Ilsoe - Carnegie Investment Bank Rajat Sharma - Goldman Sachs Anna Krassowska Welcome and thank you for joining us today to discuss Zealand's Interim Results for the First Quarter of 2023.

Zealand Pharma A/S (ZEAL) Q1 2023 Earnings Call Transcript

Company announcement - No. 20 / 2023 Zealand Pharma Announces Financial Results for the First Quarter of 2023 Positive topline data from obesity portfolio On track for two regulatory submissions targeting rare diseases Strengthened balance sheet with DKK 1.5 billion in April resulting in a runway to mid-2026 Copenhagen, Denmark, May 11, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma Announces Financial Results for the First Quarter of 2023

INGELHEIM, Germany, & COPENHAGEN, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight.

Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight

Press Release– No. 3 / 2023 Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results Copenhagen, Denmark, May 4, 2023 – a Zealand Pharma A/S (CVR-no.

Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results

Company announcement – No. 15 / 2023 Zealand Pharma launches long-term incentive program for Zealand's Board of Directors, Corporate Management and employees for 2023 Copenhagen, Denmark, April 19, 2023 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma launches long-term incentive program for Zealand's Board of Directors, Corporate Management and employees for 2023

Press release – No. 2 / 2023 Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference Copenhagen, Denmark, April 12, 2023 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no.

Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference

Zealand Pharma A/S publishes a listing prospectus regarding admission to trading and official listing of 6,578,948 new shares on Nasdaq Copenhagen

Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion

News for Zealand Pharma Stock (ZEAL)